547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir

類似資料

• Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
  著者:: Lagishetty, Chakradhar, 等
  出版事項: (2020)
• Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
  著者:: Sevinsky, Heather, 等
  出版事項: (2017)
• 2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
  著者:: Moore, Katy P, 等
  出版事項: (2019)
• Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
  著者:: Gartland, Margaret, 等
  出版事項: (2020)
• Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
  著者:: Moore, Katy, 等
  出版事項: (2019)